The use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer: Timing matters

Breast J. 2020 Dec;26(12):2435-2436. doi: 10.1111/tbj.14027. Epub 2020 Aug 19.
No abstract available

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Chemotherapy, Adjuvant
  • Cyclin-Dependent Kinase 4
  • Female
  • Humans
  • Protein Kinase Inhibitors / adverse effects

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Cyclin-Dependent Kinase 4